2015 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies in Kidney Transplant Recipients
The reported incidence and risk factors for the development of de novo donor specific antibodies (dnDSA) are variable. Although dnDSA is a negative predictor of…2015 American Transplant Congress
Differences in Reactivity of HLA-Specific Antibodies May Be Explained By Differences in Their Affinities for Selected Epitopes on HLA Proteins
Affinity of IgG immunoglobulins for antigen varies and matures within the evolution of immune responses. Affinity is likely to be different for different epitope-antibody interactions…2015 American Transplant Congress
Impact of Pretransplant Pregnancy On Immunization and Immunologic Outcome in Kidney Transplantation
BACKGROUND:The detailed impact of pretransplant pregnancy on HLA alloimmunization and outcome after kidney transplantation is so far not well known.PATIENTS AND METHODS:A retrospective single center…2015 American Transplant Congress
Pre-Transplant Donor Specific Antibody With Negative Flow-Crossmatch Was Related to Higher Acute Rejection But Not to Poor Graft Survival
Background: DSA have been associated to lower graft survival and a higher humoral rejection rate, but there is a concern about the clinical impact of…2015 American Transplant Congress
First Clinical Data With an Improved C1q-Luminex® Assay
1Nephrology, Charite Hospital, Berlin, Germany; 2HLA Laboratory, Charite Hospital, Berlin, Germany.
Background: Chronic allograft dysfunction remains the main obstacle for long-term success of kidney transplantation. Immunological factors, in particular HLA-antibodies, contribute to long-term allograft loss. Identification…2015 American Transplant Congress
Accurate Prediction of High-Resolution HLA-A, -B, -C, -DRB1 and -DQB1 Typing and Low-Resolution HLA-DQA1 Typing by Haplotype Analysis
Aim: Allele-specific HLA antibodies are commonly detected by Luminex single antigen bead assays in solid organ transplant recipients. However, high-resolution HLA typing for deceased donors…2015 American Transplant Congress
Donor-Specific Alloantibody After Positive Crossmatch Kidney Transplantation With Eculizumab (EC): Correlation With Transplant Glomerulopathy and Graft Failure
1Mayo Clinic, Rochester, MN; 2Paul Terasaki Foundation, Los Angeles, CA.
Introduction. EC (C5 blockade) reduces the incidence of early clinical acute antibody mediated rejection (AMR) after +XMKTx, but does not prevent chronic AMR. We examined…2015 American Transplant Congress
Improved Long-Term Graft Survival in Renal Transplant Recipients With Donor Specific Antibodies (DSA) After Mycophenolic Acid Escalation
Background: DSA formation in post-renal transplant patients is associated with chronic rejection and graft failure. Previous studies in our population indicate DSA formation is a…2015 American Transplant Congress
Cyclophosphamide as a Salvage Therapy for Combined Intravenous Immunoglobulins and Plasmapheresis Refractory Antibody-Mediated Rejection
Acute antibody-mediated rejection (AMR) poses a significant risk to graft survival. Current or standard treatment (ST) of AMR currently consists of plasmapheresis (PP), intravenous immunoglobulin…2015 American Transplant Congress
Both Preformed and De Novo Cw Donor Specific Antibodies Are Clinically Significant in Renal Transplantation
Imperial College Kidney and Transplant Centre, Imperial College NHS, London, United Kingdom.
Preformed [PF] and de novo [DN] anti-HLA A, B, DR and DQ donor specific antibodies [DSAbs] are associated with poorer allograft outcomes secondary to antibody…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- 47
- Next Page »